{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:08:44Z","timestamp":1785884924683,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malignant mesothelioma is an aggressive cancer with poor prognosis. It is characterized by prominent extracellular matrix, mesenchymal tumor cell phenotypes and chemoresistance. In this study, the ability of pirfenidone to alter mesothelioma cell proliferation and migration as well as mesothelioma tumor microenvironment was evaluated. Pirfenidone is an anti-fibrotic drug used in the treatment of idiopathic pulmonary fibrosis and has also anti-proliferative activities. Mesothelioma cell proliferation was decreased by pirfenidone alone or in combination with cisplatin. Pirfenidone also decreased significantly Transwell migration\/invasion and 3D collagen invasion. This was associated with increased BMP pathway activity, decreased\n                    <jats:italic>GREM1<\/jats:italic>\n                    expression and downregulation of MAPK\/ERK and AKT\/mTOR signaling. The canonical Smad-mediated TGF-\u03b2 signaling was not affected by pirfenidone. However, pirfenidone blocked TGF-\u03b2 induced upregulation of ERK and AKT pathways. Treatment of mice harboring mesothelioma xenografts with pirfenidone alone did not reduce tumor proliferation\n                    <jats:italic>in vivo<\/jats:italic>\n                    . However, pirfenidone modified the tumor microenvironment by reducing the expression of extracellular matrix associated genes. In addition,\n                    <jats:italic>GREM1<\/jats:italic>\n                    expression was downregulated by pirfenidone\n                    <jats:italic>in vivo<\/jats:italic>\n                    . By reducing two major upregulated pathways in mesothelioma and by targeting tumor cells and the microenvironment pirfenidone may present a novel anti-fibrotic and anti-cancer adjuvant therapy for mesothelioma.\n                  <\/jats:p>","DOI":"10.1038\/s41598-018-28297-x","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T10:37:58Z","timestamp":1530095878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo"],"prefix":"10.1038","volume":"8","author":[{"given":"Chang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Rezov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmi","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-6965","authenticated-orcid":false,"given":"Ville","family":"Vartiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"R\u00f6nty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjukka","family":"Myll\u00e4rniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katri","family":"Koli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"28297_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","volume":"182","author":"BT Mossman","year":"2013","unstructured":"Mossman, B. T. et al. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol 182, 1065\u20131077, https:\/\/doi.org\/10.1016\/j.ajpath.2012.12.028 (2013).","journal-title":"Am J Pathol"},{"key":"28297_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1183\/09059180.00007014","volume":"24","author":"OD Roe","year":"2015","unstructured":"Roe, O. D. & Stella, G. M. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev 24, 115\u2013131, https:\/\/doi.org\/10.1183\/09059180.00007014 (2015).","journal-title":"Eur Respir Rev"},{"key":"28297_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/modpathol.2009.180","volume":"23","author":"S Klebe","year":"2010","unstructured":"Klebe, S. et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol 23, 470\u2013479, https:\/\/doi.org\/10.1038\/modpathol.2009.180 (2010).","journal-title":"Mod Pathol"},{"key":"28297_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","volume":"137","author":"AN Husain","year":"2013","unstructured":"Husain, A. N. et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 137, 647\u2013667, https:\/\/doi.org\/10.5858\/arpa.2012-0214-OA (2013).","journal-title":"Arch Pathol Lab Med"},{"key":"28297_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 17, 475\u2013488, https:\/\/doi.org\/10.1038\/nrc.2017.42 (2017).","journal-title":"Nat Rev Cancer"},{"key":"28297_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ijc.23949","volume":"124","author":"SV Ivanov","year":"2009","unstructured":"Ivanov, S. V. et al. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 124, 589\u2013599, https:\/\/doi.org\/10.1002\/ijc.23949 (2009).","journal-title":"Int J Cancer"},{"key":"28297_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1349-7006.2009.01336.x","volume":"101","author":"Y Sekido","year":"2010","unstructured":"Sekido, Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 101, 1\u20136, https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01336.x (2010).","journal-title":"Cancer Sci"},{"key":"28297_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1165\/ajrcmb.12.5.7742009","volume":"12","author":"DR Fitzpatrick","year":"1995","unstructured":"Fitzpatrick, D. R., Peroni, D. J. & Bielefeldt-Ohmann, H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 12, 455\u2013460, https:\/\/doi.org\/10.1165\/ajrcmb.12.5.7742009 (1995).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"28297_CR9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1476-5381.2012.01873.x","volume":"166","author":"RE Favoni","year":"2012","unstructured":"Favoni, R. E., Daga, A., Malatesta, P. & Florio, T. Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. Br J Pharmacol 166, 532\u2013553, https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01873.x (2012).","journal-title":"Br J Pharmacol"},{"key":"28297_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.yexcr.2014.12.010","volume":"332","author":"JA Tamminen","year":"2015","unstructured":"Tamminen, J. A. et al. Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth. Exp Cell Res 332, 102\u2013115, https:\/\/doi.org\/10.1016\/j.yexcr.2014.12.010 (2015).","journal-title":"Exp Cell Res"},{"key":"28297_CR11","doi-asserted-by":"publisher","first-page":"98280","DOI":"10.18632\/oncotarget.21550","volume":"8","author":"M Yin","year":"2017","unstructured":"Yin, M. et al. Gremlin-1 is a key regulator of the invasive cell phenotype in mesothelioma. Oncotarget 8, 98280\u201398297, https:\/\/doi.org\/10.18632\/oncotarget.21550 (2017).","journal-title":"Oncotarget"},{"key":"28297_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.29","volume":"2","author":"JA Tamminen","year":"2013","unstructured":"Tamminen, J. A. et al. Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. Oncogenesis 2, e66, https:\/\/doi.org\/10.1038\/oncsis.2013.29 (2013).","journal-title":"Oncogenesis"},{"key":"28297_CR13","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu, G. et al. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 192, e3\u201319, https:\/\/doi.org\/10.1164\/rccm.201506-1063ST (2015).","journal-title":"Am J Respir Crit Care Med"},{"key":"28297_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2353\/ajpath.2006.051263","volume":"169","author":"K Koli","year":"2006","unstructured":"Koli, K. et al. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 169, 61\u201371, https:\/\/doi.org\/10.2353\/ajpath.2006.051263 (2006).","journal-title":"Am J Pathol"},{"key":"28297_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1164\/rccm.200706-945OC","volume":"177","author":"M Myll\u00e4rniemi","year":"2008","unstructured":"Myll\u00e4rniemi, M. et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 177, 321\u2013329, https:\/\/doi.org\/10.1164\/rccm.200706-945OC (2008).","journal-title":"Am J Respir Crit Care Med"},{"key":"28297_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1165\/rcmb.2012-0201OC","volume":"48","author":"O Lepp\u00e4ranta","year":"2013","unstructured":"Lepp\u00e4ranta, O., Tikkanen, J. M., Bespalov, M. M., Koli, K. & Myll\u00e4rniemi, M. Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo. Am J Respir Cell Mol Biol 48, 448\u2013455, https:\/\/doi.org\/10.1165\/rcmb.2012-0201OC (2013).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"28297_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1172\/JCI93554","volume":"128","author":"M Yamauchi","year":"2018","unstructured":"Yamauchi, M., Barker, T. H., Gibbons, D. L. & Kurie, J. M. The fibrotic tumor stroma. J Clin Invest 128, 16\u201325, https:\/\/doi.org\/10.1172\/JCI93554 (2018).","journal-title":"J Clin Invest"},{"key":"28297_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/PPA.S37233","volume":"8","author":"Y Takeda","year":"2014","unstructured":"Takeda, Y., Tsujino, K., Kijima, T. & Kumanogoh, A. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence 8, 361\u2013370, https:\/\/doi.org\/10.2147\/PPA.S37233 (2014).","journal-title":"Patient Prefer Adherence"},{"key":"28297_CR19","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21, 2636\u20132644, https:\/\/doi.org\/10.1200\/JCO.2003.11.136 (2003).","journal-title":"J Clin Oncol"},{"key":"28297_CR20","doi-asserted-by":"publisher","unstructured":"Zhang, Y. E. Non-Smad Signaling Pathways of the TGF-beta Family. Cold Spring Harb Perspect Biol 9, https:\/\/doi.org\/10.1101\/cshperspect.a022129 (2017).","DOI":"10.1101\/cshperspect.a022129"},{"key":"28297_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00441-011-1201-y","volume":"347","author":"Y Mu","year":"2012","unstructured":"Mu, Y., Gudey, S. K. & Landstrom, M. Non-Smad signaling pathways. Cell Tissue Res 347, 11\u201320, https:\/\/doi.org\/10.1007\/s00441-011-1201-y (2012).","journal-title":"Cell Tissue Res"},{"key":"28297_CR22","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3978\/j.issn.2072-1439.2015.02.19","volume":"7","author":"H Batra","year":"2015","unstructured":"Batra, H. & Antony, V. B. Pleural mesothelial cells in pleural and lung diseases. J Thorac Dis 7, 964\u2013980, https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2015.02.19 (2015).","journal-title":"J Thorac Dis"},{"key":"28297_CR23","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","volume":"20","author":"A de Reynies","year":"2014","unstructured":"de Reynies, A. et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 20, 1323\u20131334, https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2429 (2014).","journal-title":"Clin Cancer Res"},{"key":"28297_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2016.04.018","volume":"63","author":"MA Hoda","year":"2016","unstructured":"Hoda, M. A. et al. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. Eur J Cancer 63, 64\u201373, https:\/\/doi.org\/10.1016\/j.ejca.2016.04.018 (2016).","journal-title":"Eur J Cancer"},{"key":"28297_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","volume":"58","author":"E Conte","year":"2014","unstructured":"Conte, E. et al. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 58, 13\u201319, https:\/\/doi.org\/10.1016\/j.ejps.2014.02.014 (2014).","journal-title":"Eur J Pharm Sci"},{"key":"28297_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1023\/A:1007068313370","volume":"24","author":"SN Iyer","year":"2000","unstructured":"Iyer, S. N., Hyde, D. M. & Giri, S. N. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 24, 477\u2013491 (2000).","journal-title":"Inflammation"},{"key":"28297_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2162-z","volume":"16","author":"M Mediavilla-Varela","year":"2016","unstructured":"Mediavilla-Varela, M., Boateng, K., Noyes, D. & Antonia, S. J. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer 16, 176, https:\/\/doi.org\/10.1186\/s12885-016-2162-z (2016).","journal-title":"BMC Cancer"},{"key":"28297_CR28","doi-asserted-by":"publisher","unstructured":"Surolia, R. et al. 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI Insight 2, https:\/\/doi.org\/10.1172\/jci.insight.94088 (2017).","DOI":"10.1172\/jci.insight.94088"},{"key":"28297_CR29","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1158\/0008-5472.CAN-12-3180","volume":"73","author":"S Kozono","year":"2013","unstructured":"Kozono, S. et al. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res 73, 2345\u20132356, https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3180 (2013).","journal-title":"Cancer Res"},{"key":"28297_CR30","doi-asserted-by":"publisher","first-page":"840","DOI":"10.7150\/ijms.11579","volume":"12","author":"DA Lopez-de la Mora","year":"2015","unstructured":"Lopez-de la Mora, D. A. et al. Role and New Insights of Pirfenidone in Fibrotic Diseases. Int J Med Sci 12, 840\u2013847, https:\/\/doi.org\/10.7150\/ijms.11579 (2015).","journal-title":"Int J Med Sci"},{"key":"28297_CR31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","volume":"291","author":"SN Iyer","year":"1999","unstructured":"Iyer, S. N., Gurujeyalakshmi, G. & Giri, S. N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291, 367\u2013373 (1999).","journal-title":"J Pharmacol Exp Ther"},{"key":"28297_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12931-016-0328-5","volume":"17","author":"ST Lehtonen","year":"2016","unstructured":"Lehtonen, S. T. et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res 17, 14, https:\/\/doi.org\/10.1186\/s12931-016-0328-5 (2016).","journal-title":"Respir Res"},{"key":"28297_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","volume":"57","author":"L Knuppel","year":"2017","unstructured":"Knuppel, L. et al. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly. Am J Respir Cell Mol Biol 57, 77\u201390, https:\/\/doi.org\/10.1165\/rcmb.2016-0217OC (2017).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"28297_CR34","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1096\/fj.201600892RR","volume":"31","author":"M Didiasova","year":"2017","unstructured":"Didiasova, M. et al. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB J 31, 1916\u20131928, https:\/\/doi.org\/10.1096\/fj.201600892RR (2017).","journal-title":"FASEB J"},{"key":"28297_CR35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3109\/0886022X.2012.718955","volume":"34","author":"K Takakura","year":"2012","unstructured":"Takakura, K., Tahara, A., Sanagi, M., Itoh, H. & Tomura, Y. Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells. Ren Fail 34, 1309\u20131316, https:\/\/doi.org\/10.3109\/0886022X.2012.718955 (2012).","journal-title":"Ren Fail"},{"key":"28297_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/ATVBAHA.113.302517","volume":"34","author":"M Corsini","year":"2014","unstructured":"Corsini, M. et al. Cyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin. Arterioscler Thromb Vasc Biol 34, 136\u2013145, https:\/\/doi.org\/10.1161\/ATVBAHA.113.302517 (2014).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"28297_CR37","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1158\/0008-5472.CAN-15-0858","volume":"75","author":"T Yamada","year":"2015","unstructured":"Yamada, T. et al. Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. Cancer Res 75, 4188\u20134197, https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0858 (2015).","journal-title":"Cancer Res"},{"key":"28297_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1089\/jop.2016.0107","volume":"33","author":"X Guo","year":"2017","unstructured":"Guo, X. et al. Pirfenidone Induces G1 Arrest in Human Tenon\u2019s Fibroblasts In Vitro Involving AKT and MAPK Signaling Pathways. J Ocul Pharmacol Ther 33, 366\u2013374, https:\/\/doi.org\/10.1089\/jop.2016.0107 (2017).","journal-title":"J Ocul Pharmacol Ther"},{"key":"28297_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/nep.12831","volume":"22","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis. Nephrology (Carlton) 22, 589\u2013597, https:\/\/doi.org\/10.1111\/nep.12831 (2017).","journal-title":"Nephrology (Carlton)"},{"key":"28297_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1183\/09059180.00001111","volume":"20","author":"CJ Schaefer","year":"2011","unstructured":"Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D. & Kossen, K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 20, 85\u201397, https:\/\/doi.org\/10.1183\/09059180.00001111 (2011).","journal-title":"Eur Respir Rev"},{"key":"28297_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2017.01.006","volume":"106","author":"A Fujiwara","year":"2017","unstructured":"Fujiwara, A. et al. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer. Lung Cancer 106, 8\u201316, https:\/\/doi.org\/10.1016\/j.lungcan.2017.01.006 (2017).","journal-title":"Lung Cancer"},{"key":"28297_CR42","doi-asserted-by":"publisher","first-page":"82889","DOI":"10.18632\/oncotarget.12658","volume":"7","author":"K Takai","year":"2016","unstructured":"Takai, K., Le, A., Weaver, V. M. & Werb, Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7, 82889\u201382901, https:\/\/doi.org\/10.18632\/oncotarget.12658 (2016).","journal-title":"Oncotarget"},{"key":"28297_CR43","doi-asserted-by":"publisher","first-page":"24506","DOI":"10.18632\/oncotarget.15534","volume":"8","author":"C Polydorou","year":"2017","unstructured":"Polydorou, C., Mpekris, F., Papageorgis, P., Voutouri, C. & Stylianopoulos, T. Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. Oncotarget 8, 24506\u201324517, https:\/\/doi.org\/10.18632\/oncotarget.15534 (2017).","journal-title":"Oncotarget"},{"key":"28297_CR44","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","volume":"35","author":"F Grosso","year":"2017","unstructured":"Grosso, F. et al. Nintedanib Plus Pemetrexed\/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. J Clin Oncol 35, 3591\u20133600, https:\/\/doi.org\/10.1200\/JCO.2017.72.9012 (2017).","journal-title":"J Clin Oncol"},{"key":"28297_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321, https:\/\/doi.org\/10.1093\/bioinformatics\/bts635 (2013).","journal-title":"Bioinformatics"},{"key":"28297_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140, https:\/\/doi.org\/10.1093\/bioinformatics\/btp616 (2010).","journal-title":"Bioinformatics"},{"key":"28297_CR47","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/cancers4041180","volume":"4","author":"M Milacic","year":"2012","unstructured":"Milacic, M. et al. Annotating cancer variants and anti-cancer therapeutics in reactome. Cancers (Basel) 4, 1180\u20131211, https:\/\/doi.org\/10.3390\/cancers4041180 (2012).","journal-title":"Cancers (Basel)"},{"key":"28297_CR48","doi-asserted-by":"publisher","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","volume":"46","author":"A Fabregat","year":"2018","unstructured":"Fabregat, A. et al. The Reactome Pathway Knowledgebase. Nucleic Acids Res 46, D649\u2013D655, https:\/\/doi.org\/10.1093\/nar\/gkx1132 (2018).","journal-title":"Nucleic Acids Res"},{"key":"28297_CR49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30, 207\u2013210 (2002).","journal-title":"Nucleic Acids Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28297-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28297-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:07:20Z","timestamp":1751699240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28297-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["28297"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-28297-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733574951.793548378","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"7 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10070"}}